Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000018

Drug Information
NameCAP-232
SynonymsCID6918265; TLN-232; AC1OCF7X; CAP-232; (4R,7S,10R,13S,16R)-7-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-16-[[(2R)-2-amino-3-phenylpropanoyl]amino]-13-[(4-hydroxyphenyl)methyl]-10-(1H-indol-3-ylmethyl)-6,9,12,15-tetraoxo-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide; CHEMBL539934
CompanyThallion Pharma.
IndicationRefractory Renal Cell Carcinoma
[ICD9: 189   ICD10: C64]
Phase IIa completed    
Solid Tumors
[ICD9: 140-199, 210-229   ICD10: C00-C75, C7A, C7B, D10-D36, D3A]
Phase II    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C45H58N10O9S2/c1-25(56)38(39(48)58)55-45(64)37-24-66-65-23-36(
53-40(59)31(47)19-26-9-3-2-4-10-26)44(63)51-34(20-27-14-16-29(57)
17-15-27)42(61)52-35(21-28-22-49-32-12-6-5-11-30(28)32)43(62)50-3
3(41(60)54-37)13-7-8-18-46/h2-6,9-12,14-17,22,25,31,33-38,49,56-5
7H,7-8,13,18-21,23-24,46-47H2,1H3,(H2,48,58)(H,50,62)(H,51,63)(H,
52,61)(H,53,59)(H,54,60)(H,55,64)/t25-,31-,33+,34+,35-,36+,37+,38
+/m1/s1
InChIKeySNAJPQVDGYDQSW-DYCFWDQMSA-N
Canonical SMILESCC(C(C(=O)N)NC(=O)C1CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=
CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC=CC=C5)N)O    
Isomeric SMILESC[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C
(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H]
(CC5=CC=CC=C5)N)O
Therapeutic ClassAntineoplastic Agents
PubChem Compound IDCID 6918265.
PubChem Substance IDSID 12014851.
ClinicalTrials.govNCT00422786;
NCT00735332;
TargetSomatostatin receptor type 1Agonist[1][2][3]
Somatostatin receptor type 1Multitarget[1][2][3]
Somatostatin receptor type 4Agonist[1][2][3]
Somatostatin receptor type 4Multitarget[1][2][3]
Ref 1TT-232: Somatostatin sst1/sst4 receptor agonist treatment of neuropathic pain treatment of inflammation. Drugs of the future. 2005; 30:558-66 To Reference
Ref 2Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models. Anticancer Res. 2008 Sep-Oct;28(5A):2769-74. To Reference
Ref 3Inhibitory effects of synthetic somatostatin receptor subtype 4 agonists on acute and chronic airway inflammation and hyperreactivity in the mouse. Eur J Pharmacol. 2008 Jan 14;578(2-3):313-22. Epub 2007 Oct 5. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543